- Home
- HBIO vs BOLT Comparison
HBIO vs BOLT Comparison
Compare HBIO & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBIO
- BOLT
- Stock Information
- Founded
- HBIO 1901
- BOLT 2015
- Country
- HBIO United States
- BOLT United States
- Employees
- HBIO N/A
- BOLT N/A
- Industry
- HBIO Biotechnology: Laboratory Analytical Instruments
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- HBIO Industrials
- BOLT Health Care
- Exchange
- HBIO Nasdaq
- BOLT Nasdaq
- Market Cap
- HBIO 19.6M
- BOLT 16.8M
- IPO Year
- HBIO 2000
- BOLT 2021
- Fundamental
- Price
- HBIO $0.44
- BOLT $6.19
- Analyst Decision
- HBIO Buy
- BOLT Buy
- Analyst Count
- HBIO 2
- BOLT 3
- Target Price
- HBIO $3.00
- BOLT $50.00
- AVG Volume (30 Days)
- HBIO 1.1M
- BOLT 18.9K
- Earning Date
- HBIO 08-07-2025
- BOLT 08-12-2025
- Dividend Yield
- HBIO N/A
- BOLT N/A
- EPS Growth
- HBIO N/A
- BOLT N/A
- EPS
- HBIO N/A
- BOLT N/A
- Revenue
- HBIO $91,397,000.00
- BOLT $3,638,000.00
- Revenue This Year
- HBIO N/A
- BOLT N/A
- Revenue Next Year
- HBIO $9.75
- BOLT $24.14
- P/E Ratio
- HBIO N/A
- BOLT N/A
- Revenue Growth
- HBIO N/A
- BOLT N/A
- 52 Week Low
- HBIO $0.28
- BOLT $5.20
- 52 Week High
- HBIO $3.60
- BOLT $15.60
- Technical
- Relative Strength Index (RSI)
- HBIO 49.18
- BOLT 52.70
- Support Level
- HBIO $0.42
- BOLT $5.68
- Resistance Level
- HBIO $0.48
- BOLT $6.40
- Average True Range (ATR)
- HBIO 0.05
- BOLT 0.30
- MACD
- HBIO -0.01
- BOLT 0.09
- Stochastic Oscillator
- HBIO 24.69
- BOLT 79.81
About HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.